Back to Search
Start Over
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
- Source :
- Diabetes, Obesity & Metabolism
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Aim To investigate the efficacy and safety of initiating insulin degludec/liraglutide (IDegLira) in patients with type 2 diabetes (T2D) who had discontinued pretrial sulphonylureas (SUs) or dipeptidyl peptidase‐4 inhibitors (DPP4is) versus patients not previously treated with these regimens. Materials and Methods In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U). In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add‐on to sodium‐glucose co‐transporter‐2 inhibitors ± oral antidiabetic drugs. In this post hoc analysis, patients were grouped according to pretrial use of SU (DUAL II) or DPP4i (DUAL IX). Results Regardless of pretrial SU/DPP4i use, IDegLira was favourable versus insulin comparators with respect to change in HbA1c and body weight. Lower hypoglycaemia rates and comparable end‐of‐trial daily insulin dose were achieved with IDegLira, regardless of pretrial regimen. There was no clinically relevant increase in mean self‐measured blood glucose in the early weeks after IDegLira initiation. There was no statistically significant interaction between the randomized treatments and previous SU/DPP4i use. Conclusions IDegLira was more favourable compared with degludec or glargine U100 in terms of change in HbA1c and body weight, regardless of antecedent treatment. Clinicians should be aware of a potential transient rise in self‐measured blood glucose when transitioning therapy in patients. This shows that SUs/DPP4is can be safely discontinued, without deterioration in glycaemic control when initiating IDegLira, allowing a simplified treatment regimen.
- Subjects :
- Blood Glucose
Insulin degludec
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Urology
030209 endocrinology & metabolism
glucagon‐like peptide‐1 analogue
Type 2 diabetes
030204 cardiovascular system & hematology
law.invention
03 medical and health sciences
0302 clinical medicine
Endocrinology
Randomized controlled trial
law
randomized trial
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
liraglutide
business.industry
Liraglutide
Insulin glargine
Insulin
Original Articles
medicine.disease
Metformin
Insulin, Long-Acting
Drug Combinations
Regimen
Diabetes Mellitus, Type 2
insulin therapy
Original Article
type 2 diabetes
business
medicine.drug
Subjects
Details
- ISSN :
- 14631326 and 14628902
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Diabetes, Obesity and Metabolism
- Accession number :
- edsair.doi.dedup.....3e42a11f2f68a49592638e45b4dfc998